Hemostatics
Hemostatics is developing a novel antifibrinolytic agent to reduce bleeding in life-threatening and disabling haemorrhagic conditions. Thanks to an innovative mechanism of action to inhibit fibrinolysis, our patented preclinical candidate is aiming to address a number of significant unmet medical needs in trauma, surgery, ICH, PPH, GI bleeding and in several bleeding disorders (Rare Diseases).
7-day free trial · no credit card
Verified contacts
6
available on Kipplo
LinkedIn employees
10
1 to 10 range
Open roles
—
no listings
Distinct roles
6
indexed titles
Tech stack
0
tools in use
Monthly traffic
—
organic / mo
Sign up free to see all 6 verified contacts at Hemostatics
Free for 7 days · 50 credits · no card · only pay for verified records.
Decision-makers and verified team members
6 contacts with verified email or phone · masked until revealed.
- JD
Jeannett Dimsits
Board Member and Senior Advisor · General Business & Management
EmailPhone - AT
Adriana Temporão
Scientific and Clinical Project Manager · Other
EmailPhone - GO
Gregorio Oliveira
Board Member Hemostatics · General Business & Management
EmailPhone - NS
Nicolas Saglio
Chief Executive Officer · Other
EmailPhone
Showing 4 of 6 verified contacts
Top roles at Hemostatics
6 distinct titles indexed · top 6 shown.
- 1board member and senior advisor
- 1board member hemostatics
- 1chief executive officer
- 1chief scientific officer
- 1cmo
- 1scientific and clinical project manager
Sign up to unlock all 6 contacts at Hemostatics
Free for 7 days · 50 credits · no card · only pay for verified records.
Sign up to reveal 6 verified contacts at Hemostatics
7-day trial · no credit card · cancel anytime · only pay for verified records.
Trusted by sales, marketing, and GTM engineering teams.